论文部分内容阅读
本文对22例高血压病人口服活性血管紧张素转换酶抑制剂(ACEI)CaptoPril(SQ 14225)的抗高血压效果进行了评价,其中对17例进行了为期1~7个月的随访。22例中包括8例原发性高血压,8例肾血管性高血压和6例慢性肾功能衰竭伴发之高血压。服药后,全部病人包括低肾素者在内的血压均有明显下
In this paper, the antihypertensive efficacy of CaptoPril (SQ 14225), an orally active angiotensin-converting enzyme inhibitor (ACEI), was evaluated in 22 hypertensive patients, of which 17 were followed up for 1 to 7 months. Twenty-two patients included eight patients with essential hypertension, eight with renovascular hypertension and six with hypertension associated with chronic renal failure. After taking the medication, all patients, including those with low renin blood pressure were significantly lower